Fractyl Health Publishes Two-Year Durability Data After a Single Revita DMR® Therapeutic Procedure in Patients with Type 2 Diabetes

February 1, 2022

REVITA-1 was an open-label cohort study evaluating Revita® in patients with type 2 diabetes on oral anti-diabetic agents but not yet on insulin
More »

Antios Therapeutics Doses First Patients in SAVE 1, a Phase 2a Study of ATI-2173 in Patients with Chronic Hepatitis B Virus (HBV)

April 21, 2021

SAVE 1 to evaluate ATI-2173 in combination with tenofovir (TDF) vs. TDF plus placebo
More »

Antios Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering ATI-2173

February 24, 2020

Antios Therapeutics, Inc. ("Antios"), announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent titled, "Phosphoramidates for the Treatment of Hepatitis B Virus."
More »